| Alkaloid (11) |  |
| Allergan (6) | |
| Astrazeneca (7) | |
| Basi (302) | |
| Bayer (10) | |
| F hoffmann la roche ltd (24) | |
| Glaxosmithkline (15) | |
| Novartis (22) | |
| Pfizer (10) | |
| Sanofi (5) | |
| Alkaloid (11) | |
| Allergan (6) | |
| Astrazeneca (7) | |
| Basi (302) | |
| Bayer (10) | |
| F hoffmann la roche ltd (24) | |
| Glaxosmithkline (15) | |
| Novartis (22) | |
| Pfizer (10) | |
| Sanofi (5) | |
and will be run by Arthur Levinson, chairman and ex-CEO of biotech company Genentech. Google gave exclusive access to Time magazine for a story on the new venture.
Arthur D. Levinson, Chairman and former CEO of Genentech and Chairman of Apple, will be Chief executive officer and a founding investor.
Art Levinson will remain Chairman of Genentech and a director of Hoffmann-la roche, as well as Chairman of Apple.
rt track record at Genentech has been exemplary, and we see an interesting potential for our companies to work together going forward.
Art Levinson, Chairman and former CEO of Genentech and Chairman of Apple, will be Chief executive officer. OK so youe probably thinking wow!
, GE, Genentech, Grace, Merck & co.,and Sartorius-Stedim was prompted by a $7. 9m grant from DARPA, the US Defense Advanced Research Projects Agency.
, Fluorometric, GE, Genentech, Grace, Merck & co.,, and Sartorius-Stedim was prompted by a $7. 9m grant from DARPA, the US Defense Advanced Research Projects Agency.
#Genentech???s Alectinib Shrank Tumors in Nearly Half of Patients With Specific Lung cancer Mutation Genentech Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People With Specific Type of Lung cancer--Alectinib showed response rates of up to
69 percent in the central nervous system (CNS) in people with advanced ALK-positive non-small cell lung cancer---Genentech plans to submit these Phase I/II data to the FDA as part of a New
Drug Application for alectinib, which has been granted Breakthrough Therapy Designation--2015 ASCO Annual Meeting SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE)--Genentech,
a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from two pivotal studies (NP28673 and NP28761) that showed alectinib,
About Genentech in Lung cancer Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches,
About Genentech Founded more than 35 years ago Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions.
The company, a member of the Roche Group, has headquarters in South San francisco, California. For additional information about the company, please visit http://www. gene. com
#Genentech drug adds antibiotics to proteins to fight hidden bacteria Scientists at Genentech have armed the body immune system warriors with antibiotics
"says Sanjeev Mariathasan, a biologist Genentech, the biotech company behind the study. That's a big problem because drugs that are used normally against staph infections can take over four hours to work far longer than it takes for Staph bacteria to move into new cells,
Genentech manufactured antibodies based on those the immune system makes to combat staph infections. Then, the researchers attached the antibiotics to the antibody by using amino acids as glue.
but he says that Genentech is interested"obviously in whether this translates into human results.""In addition, the drug is very specific,
and its Genentech subsidiary from marketing the top three cancer treatments: Rituxan (rituximab, co-marketed with Biogen and ranked#4), Avastin (bevacizumab;#
Genentech spokeswoman Susan Willson told GEN. Roche has based an indication pricing system in Italy, she said,
Genentech provided its medicines to more than 180,000 people last year for free or reduced cost. Willson noted that the Genentech Access to Care Foundation recently changed its financial criteria with the goal of helping more people, n recognition of the changing healthcare environment and the increasing number of people with high out
-of-pocket costs. The cancer drug placing lowest on the list of top sellers was Novartisgleevec (imatinib mesylate,#15),
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011